Novo Nordisk tests the efficacy of its weight loss medication on alcoholic liver disease
老蟹2017
发表于 2024-5-15 17:18:05
1301
0
0
On May 15th, it was reported that Novo Nordisk is conducting trials on its weight loss drugs to explore whether they can reduce alcohol intake and treat alcoholic liver disease. The company is seeking to expand the use of these best-selling drugs.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Lilly Weight Loss Medicine Approved by US FDA, Developed by Domestic Pharmaceutical Companies Press "Acceleration Key"
- Top 20 US Stock Deals: Pfizer Encounters Double Killing Lawsuit between Diet Drugs and COVID-19 Vaccine
- Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
- Can Smegglutide Help Quit Alcohol? Novo Nordisk's latest liver disease research will provide answers
- Lilly: We have applied to the FDA for the weight loss drug Zepbound to treat sleep apnea, and it is expected to be approved as early as the end of the year
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
